XTalks

JANUARY 26, 2024

Innovations in Cancer Therapy CRISPR/Cas9, a groundbreaking gene-editing technology, has demonstrated significant potential in oncology, offering new avenues for cancer treatment. By editing these genes, researchers can effectively neutralize their cancer-promoting effects.

Research 118

Research Gene Editing Gene Genetics 118

Drug Discovery World

JULY 24, 2023

Ginkgo will leverage innovative technologies enabled by its high-throughput, automated Foundry and its proprietary genetic data Codebase, a portfolio of reusable biological assets which includes more than one billion proprietary gene sequences.

Protein 52

Protein Manufacturing Gene Sequencing Production 52

Drug Discovery World

APRIL 14, 2023

Carl H June, MD, FAACR – Lifetime Achievement in Cancer Research June, a Fellow of the AACR Academy, is the Richard W Vague Professor in Immunotherapy, Director of the Center for Cellular Immunotherapies, and Director of the Parker Institute for Cancer Immunotherapy in the Perelman School of Medicine at the University of Pennsylvania.

Genetics 52

Genetics Research Medicine Clinical Research 52

XTalks

NOVEMBER 7, 2022

Such information can reveal details about tumor staging, tumor progression, heterogeneity, gene mutations and clonal evolution. Dr. Bahassi explained that technological advances in genetic sequencing of cfDNA have enabled liquid biopsies and led to marked increase in the detection of therapeutically-targetable mutations.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Delveinsight

DECEMBER 10, 2020

Scientists at the University of Utah School of Medicine have found a way to control that autoimmune response by aiming a protein that is vital for T-cell activation. UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3. Its recent data infer that it could work for patients considered unsuited for gene therapy.

Gene Therapy 52

Gene Therapy Gene Vaccination Vaccine 52

The Pharma Data

AUGUST 15, 2021

target genes associated with cellular proliferation, angiogenesis and tumor growth. The major efficacy endpoint for the treatment of VHL-associated RCC was ORR measured by radiology assessment using RECIST v1.1 This is a rare genetic disease with an estimated incidence of 10,000 people in the U.S. WELIREG is the first HIF-2?

Hormones 52

Hormones Clinical Trials Clinical Trials Trials 52

XTalks

AUGUST 30, 2022

We know that a lot of different pathologies, especially as we’ve entered the era of molecular medicine and gene therapies, cause many of the same symptoms and work through final common pathways. Viral Vectors for Gene Delivery to the CNS. Targeting the CNS directly has been successful in modern medicine.

Trials 83

Trials Drug Delivery Drugs Gene 83